Zenas BioPharma, Inc.
NASDAQ:ZBIOBiotechnology
+$0.64 today
- Market cap
- $1.79B
- Beta
- -0.69
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$7.64
Volume 0.48M
Average 0.71M
ZBIO Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Zenas BioPharma, Inc.NASDAQ: ZBIO
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income grows, but more slowly than its trailing trend
Q1 FY2026 net income of $80.99M (cash outflow) rose 141.2% year over year, behind the +161.2% change in trailing-twelve-month net income. Sequentially, it fell 66.3% from the prior quarter. Over 3 fiscal years it compounded at +46.8% a year.
Context
- Net income amounted to 3777.4% of revenue in FY2025, up 637.6 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 4 analysts of -$272.22M (-27.9%) for the fiscal year ending Dec 2026, a slowdown from the +140.6% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$80.99M-66.3% QoQ
- Last fiscal yearDec 2025
- -$377.74M+140.6% YoY
- LTMMar 2026
- -$425.15M+161.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +141.2% | +42.2% | -99.1 pp |
| 1 year | +140.6% | -27.9% | -168.5 pp |
| 3-year CAGR | +46.8% | -21.8% | -68.7 pp |
| 5-year CAGR | -42.2% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (377.74M) USD
- Year-over-year change
- -140.6%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (377.74M) | -140.6% |
| FY2024 | 2024-12-31 | (156.99M) | -322.9% |
| FY2023 | 2023-12-31 | (37.12M) | +68.9% |
| FY2022 | 2022-12-31 | (119.28M) | — |
Net Income vs competitors
How ZBIO compares with its peers on the latest reported figures
- ZBIO's LTM Mar 2026 net income of $425.15M is the 2nd largest of the 8 companies compared; the peer median is $156.76M.
- Its year-over-year change of +161.2% is the highest of 8, against a peer median of +17.4%.
- Over three fiscal years its annual growth of +46.8% compares with a peer median of +13.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $508.96M | +9.5% | +33.8% | 7173.5% | |
| LTM Mar 2026 | $425.15M | +161.2% | +46.8% | — | |
| LTM Mar 2026 | $196.48M | +17.4% | +13.3% | — | |
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | $166.09M | +1.5% | — | — |
UPBUpstream Bio, Inc. | LTM Mar 2026 | $156.76M | +98.0% | +81.8% | 4719.0% |
| LTM Mar 2026 | $69.66M | -46.5% | -9.3% | 832.6% | |
| LTM Mar 2026 | $33.24M | +155.6% | — | 61.9% | |
| FY2025 | $18.43M | +94.4% | +13.7% | — | |
| Peer median (excluding ZBIO) | $156.76M | +17.4% | +13.7% | 2775.8% | |
Competitors are the stored peer set for ZBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (119.28M) | (37.12M) | (156.99M) | (377.74M) |
| Depreciation & Amortization | 78K | 113K | 137K | (1.88M) |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 737K | 3.5M | 10.82M | 26.35M |
| Change in Working Capital | 7.97M | (8.04M) | 25.43M | 951K |
| Accounts Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.09M | (418K) | 11.74M | (10.04M) |
| Other Working Capital | 6.88M | (7.62M) | 13.69M | 10.99M |
| Other Non-Cash Items | 44.85M | 11.03M | 925K | 179.98M |
| Operating Cash Flow | (65.65M) | (30.53M) | (119.67M) | (172.33M) |
| Capital Expenditures | (2.2M) | (17K) | (131K) | (18K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (36.42M) | (417.76M) |
| Sales of Investments | 0 | 0 | 6M | 200.89M |
| Other Investing Activities | (2M) | 0 | 0 | (35M) |
| Investing Cash Flow | (2.2M) | (17K) | (30.55M) | (251.89M) |
| Debt Repayment | 0 | 20M | 0 | 0 |
| Common Stock Issued | 59.39M | 116K | 240.64M | 152.95M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | (6.06M) | 62.34M |
| Financing Cash Flow | 59.39M | 20.12M | 412.96M | 215.28M |
| Effect of Forex Changes | (41K) | 78K | 157K | (252K) |
| Net Change in Cash | (8.5M) | (10.35M) | 262.89M | (209.19M) |
| Free Cash Flow | (67.85M) | (30.55M) | (119.81M) | (172.35M) |
Zenas BioPharma, Inc.
NASDAQ:ZBIO
Intrinsic Alpha fair value
Locked
Current Price
$26.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.